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Key messages: 46 
- Although point-of-care HIV testing is critical for expanding access to infant HIV 47 
diagnosis, misdiagnoses and associated excess costs can be substantial, and stock-outs 48 
and screening interruptions lead to substantial missed cases.  49 
- The study examines the cost-effectiveness of quality assurance systems for early 50 
infant diagnosis in five African countries with varying health systems and HIV 51 
prevalence rates.  52 
- Our study helps to inform countries, programmes and key stakeholders on the cost of 53 
quality monitoring systems and highlights the value of implementing sustainable 54 
programs to ensure accurate and uninterrupted diagnostic testing.   55 
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OBJECTIVES: Scaling up of point-of-care testing (POCT) for early infant diagnosis of HIV 64 
(EID) could reduce the large gap in infant testing. However, suboptimal POCT EID could 65 
have limited impact and potentially high avoidable costs.  This study models the cost–66 
effectiveness of a quality assurance system to address testing performance and screening 67 
interruptions, due to e.g. supply stockouts, in Kenya, Senegal, South Africa, Uganda, 68 
Zimbabwe, with varying HIV epidemics and different health systems. 69 
METHODS:  We modelled a quality assurance system raised EID quality from suboptimal 70 
levels: i.e. from misdiagnosis rates of 5%, 10% and 20% and EID testing interruptions in 71 
months, to uninterrupted optimal performance (98.5% sensitivity, 99.9% specificity). For 72 
each country, we estimated the 1-year impact and cost-effectiveness (US$/DALY averted) of 73 
improved scenarios in averting missed HIV infections and unneeded HIV treatment costs for 74 
false positive diagnoses.  75 
RESULTS: The modelled 1-year costs of a national POCT quality assurance system range 76 
from US$69,359 in South Africa to US$334,341 in Zimbabwe. At the country-level, quality 77 
assurance systems could potentially avert between 36 and 711 missed infections (i.e. false 78 
negatives) per year and unneeded treatment costs between US$5,808 and US$739,030.  79 
CONCLUSIONS: The model estimates adding effective quality assurance systems is cost-80 
saving in four of the five countries within the first year. Starting EQA requires an initial 81 
investment but will provide a positive return on investment within five years by averting the 82 
costs of misdiagnoses and would be even more efficient if implemented across multiple 83 




Point-of-care testing (POCT) is critical for expanding access to diagnosis in low- and middle-86 
income countries (LMIC). In the case of early infant diagnosis of HIV (EID), POCT can be 87 
performed by lay providers, primary care nurses or non-healthcare professionals in 88 
decentralised and remote locations(1, 2). POCT allows infants to be tested and receive their 89 
results during the same visit, thus can be linked to care more quickly and effectively to 90 
antiretroviral treatment (ART), potentially reducing loss-to-follow-up (LtFU) (3, 4). There is 91 
increasing evidence of the cost-effectiveness EID: for example, EID with immediate ART for 92 
Thailand(5), and POCT for EID for Zimbabwe(6) although it is not clear if quality assurance 93 
has been incorporated into these EID programs. 94 
 95 
Innovation in rapid HIV virologic POCT has the potential to reduce the ‘gap’ in EID (infants 96 
born to HIV-positive women and tested for HIV-infection as a percentage of all infants born to 97 
HIV-positive women), which ranges from 13%-58% across Kenya, Senegal, South Africa, 98 
Uganda and Zimbabwe(7, 8). Although decentralised EID using dried bloodspot specimens is 99 
widely available in Africa, return of results can be slow, from weeks to months(9), and cause 100 
delays in initiating ART and ultimately to high rates of loss-to-follow up(10). For EID, this is 101 
particularly detrimental: HIV progression is rapid in undiagnosed infants(11); 30% will die by 102 
one year of age and 50% by two(12). In contrast, diagnosis at six-weeks of age with immediate 103 
ART initiation for HIV-positive infants leads to reductions in mortality and HIV 104 
progression(13).  105 
 106 
However, the rapid expansion of POCT is also sometimes associated with suboptimal 107 
screening programme performance. This can be caused by poor performance of the 108 
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diagnostic itself, the person implementing the test or screening interruptions due to 109 
instrument down-time and stock outs(14). In a review of HIV testing quality among adults, 110 
more than a third reported user errors and poor management systems, resulting in 111 
misdiagnoses(15). To our knowledge, there are no data on misdiagnosis in infants. 112 
Misdiagnosis of HIV among infants carries significant consequences. False positive results 113 
lead to stigmatisation and infants being incorrectly treated with ART, potentially for life. The 114 
consequences of unnecessary ART treatment include drug toxicity, burden of care on patients 115 
and wasted resources. Conversely, false negatives, including infants who are not screened at 116 
all, lead to missed diagnoses and potential death among HIV infected infants. Given the 117 
remote settings in which POCTs are frequently used with limited access to confirmatory 118 
testing, it is even more critical to ensure correct results by monitoring testing quality through 119 
an external quality assurance (EQA) system. EQA adds an objective external measure to 120 
quality assurance systems. The system also focuses on opportunities for improvement by 121 
identifying problems throughout the testing system and providing corrective action. 122 
 123 
While POCT brings great opportunities for reaching those with limited access, 124 
decentralisation also brings challenges of supply chain management, where the lack of a 125 
single testing component can interrupt testing for significant periods. A good quality 126 
assurance system, which may extend to connectivity (i.e. connecting diagnostic platforms 127 
with a central database), would enable testing interruptions to be identified in real time and 128 
supply issues to be rapidly corrected. Even without connectivity, the increased supervision 129 
provided through the quality assurance system may support health workers to better recognise 130 
the adverse health impact of treatment interruptions, thus improve their supply chain 131 




Quality assurance systems, including EQA, with consequent corrective action is critical if 134 
decentralized testing is to be adopted(16). EQA programmes typically include external 135 
proficiency testing programs (where providers’ proficiency is evaluated on a panel of four to 136 
six samples with known results), visits from external experts or retesting of a subset of 137 
specimens in a laboratory(17). However, at present there is no regional provision of quality 138 
assurance systems for HIV EID POCT, nor are there established norms for the size of 139 
proficiency panels or cut-offs to trigger corrective actions. This is critical because, for 140 
example, on a panel of five samples, one incorrect result can be considered to translate in 141 
clinical practice into a 20% misdiagnosis rate. While generally, quality assurance systems are 142 
considered important, the question of affordability is not resolved. Eaton showed that high 143 
costs of ART among adults with false positive HIV diagnoses quickly outweighs the cost of 144 
confirmatory testing prior to ART initiation(18). Dunning also explored the cost-145 
effectiveness of confirmatory testing at ART initiation to reduce false positive infants on 146 
ART and showed how this varied by HIV prevalence(19).  While confirmatory testing can 147 
reduce inappropriate ART initiation, it does not address missed cases due to screening 148 
interruptions or poor quality.  149 
 150 
The aim of this study was to model the incremental costs and cost-effectiveness of adding a 151 
quality assurance system, including EQA, onto EID POCT programmes in five African 152 
nations with varying HIV epidemics and responses. To the best of our knowledge, this is the 153 
first study to address the potential cost-effectiveness of improving diagnostic quality. We 154 
examined the impact on hypothesised rates of misdiagnoses in scenarios where HIV POCT 155 
was widely used for EID, but had no quality assurance system. We contrasted this with the 156 
implementation of a quality assurance system that is hypothesised to maintain high sensitivity 157 
and specificity of POCT EID, i.e. be as good as during a field based evaluation in 158 
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Mozambique (1). Although supply chain management is not within the conventional remit of 159 
EQA, in many countries, health care workers are often tasked with request supplies and 160 
initiate testing(20). Where these falter, the health consequences to infants are often unseen. 161 
To demonstrate the impact of not screening, we also modelled the impact of screening 162 
interruptions, where these may be alleviated within the quality assurance system’s 163 
supervisory activities, i.e. checking for interruptions in screening in the patient registers and 164 
inventory management (20).   165 
 166 
Methods 167 
This analysis estimates the costs of introducing national quality assurance system, with EQA,  168 
and models the incremental benefit of the quality assurance system in terms of averted 169 
DALYs and treatment costs to generate the incremental cost-effectiveness ratios (ICER) and 170 
thresholds for cost saving and cost-effectiveness.  171 
 172 
Quality assurance system and corrective action scenarios 173 
Two three-day consultations/workshops with key stakeholders, including members of 174 
national reference laboratories, QA manager and clinicians, were held aimed at strengthening 175 
quality-assurance systems in Africa, including POCT for EID. In breakout groups, 176 
participants prepared qualitative descriptions of the specific processes they wanted to cost, 177 
thinking about the resources needed at each step. Training was provided on how to collect 178 
and analyse cost data. Following the consultation, participants costed a quality assurance 179 
system that provided blinded proficiency testing panels, scored reports, and corrective action 180 
that would correct to any supply chain problems. For other components, participants 181 
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modelled the system and associated costs as suitable in their situations. Because neither 182 
POCT EID nor a quality assurance system were available at the time of the consultations, 183 
costs were modelled from existing data sources, primarily point-of-care platforms for CD4 184 
quantification, in each respective country. The differences between the quality assurance 185 
system, including EQA and corrective action, across countries were reflected in the variations 186 
across their costs. The number of POCT sites modelled to receive the quality assurance 187 
system varied from 36 in Senegal to 360 in Zimbabwe (Table 1), with the total annual EID 188 
tests performed estimated to range from 1,800 in South Africa to 50,000 in Uganda. Though 189 
countries planned varying frequency of quality assurance system monitoring rounds, for the 190 
purpose of this paper these rounds have been standardised to two annually. The approaches to 191 
modelling corrective action also varied according to additional supervisory visits (1-2), 192 
instrument maintenance (0-1), machine replacement (0-1), refresher trainings (0-1), as well as 193 
variations in prices. After these costs were collected, participants were led through the cost 194 
analysis and modelling with support from an experienced economist (STR).  195 
 196 
Cost estimations 197 
Costs were estimated from a provider’s perspective over a one-year period. All costs are 198 
presented in 2016 US dollars (US$). Data were collated between March and May 2016 across 199 
Kenya, Senegal, South Africa, Uganda and Zimbabwe. The ingredients-based costing 200 
categorised cost inputs as: one-off start-up (mainly training), capital (equipment and 201 
vehicles), recurrent (supplies, transport and staff) at both reference laboratory and clinic level 202 
and by quality assurance system activity. Standardised cost assumptions across countries 203 
were the diagnostic platform costs US$20,000, a diagnostic cartridge costs US$20 (one 204 
needed per EID test), and single three-member panel is needed for checking testing 205 
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performance at each site per quality assurance monitoring round (US$10 each). A 10% 206 
wastage rate was applied to the supplies used.  207 
 208 
The Model 209 
An excel spreadsheet model was developed as a transparent approach for countries to explore 210 
the potential impact of a quality assurance system in terms of improved identification of HIV 211 
infected infants (i.e. reducing false negatives) and reduction in costs associated with not 212 
treating HIV negative infants (i.e. reducing false positives). This model is available upon 213 
request. Table 2 presents eight key country specific inputs needed, each of which can be 214 
varied as appropriate to test alternative assumptions. The model assumes that not all infants 215 
born to HIV-infected mothers would have access to EID; they need to be born to mothers 216 
who access antenatal care (ANC). Within the model, a choice can be made to model coverage 217 
of POCT EID to: only be introduced where there is a gap in EID coverage, i.e. infants born to 218 
HIV-infected mothers who attended ANC and had no EID (“the gap”), or to replace current 219 
EID, i.e. the current feasible coverage. This paper focusses on the using EID to close the gap 220 
only. Infant linkage to ART was assumed not to be affected by EID method, however the 221 
model can accommodate changes to linkage for decentralised POCT as compared to 222 
centralised laboratory testing and is explored in the univariate sensitivity analysis.  Costs of 223 
incorrectly treating HIV-negative infants can be captured over a 2, 5, 10 and 20 year period.  224 
Further details of the model are provided in Supplement 1. 225 
 226 
The model was customised with country-specific costs and epidemiological data (Table 2) 227 
and allowed estimation of the benefit of introducing a quality assurance system under a 228 
number of common challenges in HIV testing programmes. For example, what is the cost-229 
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effectiveness of the quality assurance system under misdiagnoses rates of 5%, 10%, 20%, or 230 
if programmes faced testing interruptions. Screening interruptions are modelled by in terms 231 
of a proportionate (months of screening interruptions/12 months) reduction in numbers of 232 
incorrectly treated infants and increase numbers of missed cases. This reduces the costs of 233 
excess treatment but increases DALYs lost by not identifying and treating HIV+ infants.  234 
 235 
Sensitivity analysis 236 
The model has a number of parameters that can be varied to explore their impact: treatment 237 
cost timeframe, duration of infant screening interruptions and discount rate. In the univariate 238 
sensitivity analyses, we varied the discount rate, numbers of years of treatment averted, 239 
duration of testing interruption and proportion of infants accessing ART and loss to follow-up  240 
(LtFU) on ART (on costs only). In the probabilistic sensitivity analyses, a Monte-Carlo 241 
simulation generated an incremental cost-effectiveness ratio (ICER) using a  combination of 242 
values for: years of treatment averted (mean 10; range 2-20 years), variation in the costs of 243 
quality assurance system scale up (-25%/+100%), infant treatment costs (+/- 33%), discount 244 
rate (0%-10%).  This process was repeated 1,000 times. Beta distributions were used for 245 
discount rates, and gamma distributions were used for infant treatment and quality assurance 246 
system cost. 247 
 248 
Results 249 
Costs  250 
Capital costs captured a range of costs, including vehicles used for sample transportation, 251 
EID platforms, other equipment involved (e.g. pipettes for aliquoting), and the space used for 252 
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storage of supplies and equipment. Recurrent costs reflected both the scale of the quality 253 
assurance system (i.e. number of POCT sites receiving the quality assurance system 254 
monitoring visits) and the existing health infrastructure; South Africa, for example, has a 255 
postal system allowing samples to be sent in the mail, which is less costly than transporting in 256 
programme vehicles, as was planned in other countries. On average the cost per site per 257 
quality assurance system monitoring round ranged from US$345 in South Africa to 258 
US$1,095 in Senegal. These estimates account for differences in existing infant testing 259 
services and the assumption that POCT EID would only be introduced to fill the testing gap. 260 
South Africa currently has a high EID coverage, thus could have a relatively smaller POCT 261 
EID programme, while coverage of EID in Senegal is currently very low, requiring a far 262 
larger scale up of POCT EID to address the testing gap.  263 
 264 
Effectiveness   265 
Figure 1 compares the effectiveness of implementing a quality assurance system in each 266 
setting, where we compare an EID programme with no quality assurance system, assuming 267 
no quality assurance system results using a conservative misdiagnosis rate of 5%. In the 5% 268 
misdiagnosis base-case scenario, between 53 to 757 HIV infected infants would be missed for 269 
treatment each year (represented by the size of the outer circles in figure 1.1), and 6 to 942 270 
infants could be incorrectly put on treatment depending on the country (represented by the 271 
size of the outer circles in figure 1.2). With our assumptions on sensitivity and specificity of 272 
POCT EID in the presence of EQA, misdiagnosis rates would decrease by 68% to 95%. 273 
However, even with a very strong quality assurance system, low levels of unavoidable 274 
misdiagnosis remain, with between 15 and 45 missed HIV+ infants and 2 to 47 infants 275 
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incorrectly put  on treatment (represented by the size of the inner black dots in figures 1.1 and 276 
1.2).  277 
 278 
Cost-Effectiveness 279 
Table 3 summarizes the cost and effectiveness of a quality assurance system for each country, 280 
where a quality assurance system is compared with a variety of base-case scenarios (5%, 281 
10%, 20% misdiagnosis and one month testing interruption, i.e. missing the opportunity to 282 
test eligible infants). In all countries and scenarios, introducing a quality assurance system, 283 
even if solely servicing the EID programme, would likely be highly cost-effective or cost 284 
saving, ranging from $107 per DALY averted (5% misdiagnosis in Senegal) to a savings to 285 
the health system of over US$2.7 million in the 20% misdiagnosis scenario in Uganda.    286 
 287 
A robust quality assurance system should also identify testing interruptions by assisting test 288 
providers to better manage their supply chain. If testing is not offered when the infant 289 
presents at the clinic the first time, be it for vaccination or other reasons, access to the infant 290 
is assumed lost. This is addressed in the model by translating testing interruptions into missed 291 
cases (last column in Table 3). This could avert between 1,686 and 21,095 DALYs in Senegal 292 
and Kenya, respectively.  293 
 294 
Threshold analysis 295 
For each country, a threshold reduction in misdiagnosis rate was estimated, above which 296 
quality improvements driven by an effective quality assurance system would result in the 297 
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programme saving costs. The decrease in misdiagnosis rate, regardless of the absolute 298 
misdiagnosis rates in countries, was 3.10% for Kenya, 0.91% for South Africa, 39.1% for 299 
Senegal, 1.38% for Uganda and 2.39% for Zimbabwe.   300 
The model estimated the highest quality assurance system costs that would fully cover its 301 
own costs through saving excess treatment costs (i.e. the cost of treating false positives in 302 
settings without a quality assurance system minus the cost of treating false positives with a 303 
quality assurance system). This analysis can also be seen as evaluating space for error, 304 
specifically underestimation, of the cost of the QAS.  At a 5% misdiagnosis rate, this was 305 
US$316,559 for Kenya, US$353,251 for South Africa, US$3,949 for Senegal, US$702,078 306 
for Uganda, and US$656,845 for Zimbabwe. This equates to more than 152% of the 307 
modelled quality assurance system costs in Kenya, 4% of the costs in Senegal, 509% of the 308 
cost in South Africa, 345% of the costs in Uganda, and 196% of the costs in Zimbabwe, i.e. 309 
in most countries the estimated programme costs were well below the cost-saving threshold. 310 
This does not include benefits in terms of lives saved by correctly identifying HIV infected 311 
infants who would otherwise be missed.  312 
 313 
Sensitivity analyses 314 
Table 4 presents the univariate sensitivity analysis. The quality assurance system programmes 315 
were cost saving over a range of assumptions in the discount rate, numbers of years of 316 
treatment averted, duration of testing interruption, and proportion of infants accessing ART  317 
and LfFU. With the exception of Senegal, quality assurance system for EID remains cost-318 
saving in all countries. The cost effectiveness planes for the five African nations are 319 
presented in Supplement 2, showing that the vast majority of runs in the sensitivity analysis 320 
fall in the south east quadrant, establishing that a quality assurance system, even if solely 321 
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covering the EID testing programme, is highly likely to be cost-saving, with the quality 322 
assurance system highly cost effective in Senegal.  323 
 324 
Discussion 325 
This paper illustrates the potential cost-effectiveness of introducing quality assurance systems 326 
alongside EID POCT roll out in five African nations to address the current screening gaps for 327 
EID while ensuring quality testing outside of the laboratory. We estimate the annual false 328 
negatives and false positives that could be avoided if a quality assurance system were 329 
included in each country. This translates directly into lives saved (by avoiding false 330 
negatives) and money saved (by avoiding ART costs of infants without HIV). Though each 331 
EQA round could cost between US$400 to US$1,500 per site, this investment is likely to 332 
avert between 36 and 711 missed HIV cases among infants, and even with modest rates of 333 
misdiagnoses (5%) could save up to 500,000 USD in averted health care costs attributable to 334 
treating uninfected infants. While it was not cost-saving in Senegal because of the low 335 
prevalence of HIV (with an HIV prevalence of 0.4%, only few cases of HIV in infants would 336 
be diagnosed and misdiagnosed, even in the absence of EQA), EQA was highly cost-337 
effective. In the four countries it was cost-saving, even over the short timeframe of five years.  338 
 339 
We also explore the impact of one symptom of health system that represent a number of 340 
operational challenges: screening interruptions.  This can be due to higher level inventory 341 
distribution, clinic level stock management or health worker time constraints; there are a vast 342 
range of reasons the screening may not happen.  While POCT aims to alleviate some health 343 
system constraints, the quality of the performance POCT services may still rely on these very 344 
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same health system constraints (21). A strong quality assurance system cannot be narrowly 345 
focussed on EQA but must include supportive supervision to identify and address challenges 346 
faced by health workers throughout the health system.   347 
 348 
Limitations 349 
This study has some limitations. First, there is scarcity of published data across settings for 350 
POCT for EID on the observed rates of misdiagnoses and the share of false positives and 351 
false negatives. To mitigate this, we modelled a range of misdiagnoses rates, with 352 
conservative rates as our central estimate, relative to a lower rate that would be achieved 353 
using EQA proficiency panels. There is however clear need for better information on 354 
misdiagnosis rates of POCT for EID in clinical settings and for POCT for other diseases. 355 
Moreover, the impact of identifying a problem is dependent on being able to correct it. 356 
Though costs of some corrective actions have been included (e.g. retraining of staff), other 357 
problems may be beyond the control of the quality assurance team. We assumed that six-358 
monthly quality assurance activities would be sufficient to restore and sustain diagnostic 359 
accuracy, however future models may consider a waning effect on quality in-between EQA 360 
visits. Second, this analysis only accounts for the excess treatment cost associated with a false 361 
positive result, ignoring the costs of other HIV care and social consequences of a positive 362 
HIV test, such as long term effects of social stigma and possibly lower levels of investment in 363 
these infants(22). Third, though LtFU is commonly estimated around 20% per year, we 364 
explored this impact only in the sensitivity analysis for reducing treatment costs, because 365 
estimating the health impacts of LtFU at different ages is beyond the scope of this simple 366 
model. Additionally, we applied a simplified model of the consequences of a false negative 367 
HIV result, with some assumed to immediately re-join the treatment cascade and achieve 368 
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normal life expectancy and no disability, with others being lost for good, resulting in AIDS 369 
and early death. Though the prior is likely more optimistic than reality and the latter may be 370 
more pessimistic, this was chosen as a balance between simplicity and realism in the absence 371 
of observed data. Fourth, this analysis assumes all HIV transmission occurs prior to testing, 372 
which will depend on when current EID is being performed. Guidelines suggest EID at six-373 
weeks, this analysis may then over-estimate the impact of POCT EID in identifying late 374 
infections(23). However, no consistent dataset was available to estimate only intrauterine, 375 
intrapartum and very early infections, though it is suggested to represent 80% of infant 376 
infections(23). This model aimed to be transparent while informative, and we have tested the 377 
impact of our assumptions in the PSA, which showed the results are robust to most 378 
assumptions(23).  379 
 380 
Quality assurance system in practice: capitalising on economies of scope 381 
This analysis applies the full costs of the quality assurance systems to a narrow intervention 382 
of EID testing. It is clear that a quality assurance system can achieve large economies of 383 
scope, where relatively small additional costs would be incurred to broaden the quality 384 
assurance system to address quality issues across the range of HIV testing, such as viral 385 
loads, adult HIV testing, as well as tuberculosis and malaria POCT programmes. This would 386 
greatly reduce single programme costs. Due to this narrow focus, this analysis has applied a 387 
very high cost-effectiveness bar for a quality assurance system. This is particularly relevant in 388 
low HIV prevalence setting such as Senegal, where there are relatively few infants needing 389 
testing for HIV, but a high incidence of malaria between .5% and 20% across the country’s 390 
regions (24). Were the quality assurance system to span the full HIV testing programme and 391 
beyond (e.g. malaria), its cost-effectiveness would likely become cost-saving. Other higher 392 
prevalence countries would experience even greater cost-savings. While this analysis shows 393 
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that even a very narrow quality assurance system is highly cost-effective, in practice we 394 
recommend broader quality assurance systems.   395 
 396 
Conclusion 397 
This study demonstrates the impact and cost effectiveness of averting screening interruptions 398 
and improving quality of POCT testing for EID. If the quality assurance system reduces 399 
misdiagnosis from as low as 5%, it has potential to save lives and costs in most settings. The 400 
quality assurance system will be most cost saving in countries with high HIV prevalence or 401 
where current infant testing gaps are large. Implementing broader quality assurance systems 402 
across multiple POC diagnostics in lower prevalence settings will reduce single programme 403 
costs even further.  Most importantly, when introducing POCT, ongoing support for their use 404 
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Table 1 Total and average annual quality assurance system costs in  2016 USD 514 
Cost Category 
 Kenya   Senegal   South Africa  Uganda Zimbabwe 
 USD   %   USD   %   USD   %  USD  %  USD  %  
Quality assurance system (QAS)           
Annualised Start-up Costs           
Central training $5,130 2% $12,320 12% $12,230 18% $23,541 12% $22,304 7% 
Personnel $2,476 1% $3,653 4% $5,444 8% $41,569 20% $11,032 3% 
TOTAL START-UP COSTS $7,606 4% $15,973 16% $17,674 25% $65,110 32% $33,336 10% 
Annualised Capital Costs           
Building and Storage $484 0% $533 1% $279 0% $333 0% $3,609 1% 
Equipment  $6,509 3% $1,977 2% $4,901 7% $5,412 3% $2,282 1% 
Vehicles $2,425 1% $949 1% $- 0% $1,082 1% $6,468 2% 
TOTAL CAPITAL COSTS $9,418 5% $3,459 3% $5,180 7% $6,827 3% $12,359 4% 
Recurrent Costs           
Personnel $91,458 44% $22,481 22% $16,215 23% $66,900 33% $95,691 29% 
Supplies $17,056 8% $9,526 9% $20,835 30% $15,796 8% $89,244 27% 
Recurrent Vehicle and Transport $34,016 16% $18,869 18% $- 0% $12,264 6% $2,884 1% 
Building Operation and Maintenance $37,522 18% $160 0% $2,166 3% $2,544 1% $40,204 12% 
TOTAL RECURRENT COSTS $180,052 86% $51,036 50% $39,216 57% $97,504 48% $228,023 68% 
Corrective Action Costs $11,457 5% $32,385 31% $7,288 11% $33,888 17% $60,623 18% 
TOTAL ANNUAL COSTS $208,533 100% $102,853 100% $69,358 100% $203,329 100% $334,341 100% 
           
QAS costs in perspective           
Estimated number of EID tests 36,000  1,800  23,760  50,000  30,000  
Incremental $ of QAS / EID test $5.79  $57.14  $2.92  $4.07  $11.14  
As percent of $20 EID test 28%  272%  14%  19%  53%  
Number of POCT sites 90  36  90  100  360  
$/ POCT site $2,317  $2,857  $771  $2,033  $929  
Number EQA rounds/year 2  2  2  2  2  




Table 2 Country level inputs and intermediate estimates 516 
Input Kenya Senegal South Africa Uganda Zimbabwe Source or formula 
1. Pregnancies among HIV-infected women 69,000 2,300 250,000 95,000 63,000 (25) 
2. Antenatal care coverage 96% 96% 97% 93% 94% (8) 
3. Accessible infants needing testing 63,030 1,924 213,620 102,630 64,653 =[r1]*(100%-[r2]) 
4. EID testing coverage 51% 23% 87% 48% 65% (25) 
5. EID testing gap for POCT 49% 77% 13% 52% 35% =1-[r4] 
6. Potential infants reached by POCT 20,780 1,618 28,609 50,324 33,584 =[r5]*[r3] 
7. Access to treatment - Infant 41% 26% 49% 37% 38% (25) 
8. Access to treatment – HIV-infected pregnant women 76% 55% 95% 95% 93% (25) 
9. Perinatal HIV transmission rate:  
9a. HIV-infected pregnant woman on ART 
9b. HIV-infected pregnant woman not on ART 
19.1% 
4.8%    
 
 
(26); Average (risk_start ART during 
pregnancy, risk_ART start just before 
pregnancy) 
10. Perinatal HIV transmission rate among HIV+ mothers 17% 20% 4% 8% 12% =[r8*r9a]+[(1-r8)*9b] 
Annual paediatric HIV treatment cost (includes provision) $329 $519 $898 $447 $898 Kenya (27), Senegal*, South Africa (28) 
Uganda (29), Zimbabwe [(30, 31) in (6)] 
8. Life expectancy at age 2 (in years) ** 64.7 68.5 63.8 62.3 62.6 (32) 
9. Life expectancy at age 21 (in years) 48.6 51.1 46.3 38.5 46.8 (32) 
Gross domestic product per capita (USD) $1,358 $1,067 $6,482 $727 $965 (33) 
Years of treatment costs averted 2, 5, 10, 20 2, 5, 10, 20 2, 5, 10, 20 2, 5, 10, 20 2, 5, 10, 20  
       
 [r] refers to input rows.  For a full explanation of methods for estimating years of life lost and DALYs,  see  “The model” section, within “Methods”. * personal 517 
communication Moussa Sarr.  **Life expectancy is for infants without HIV and used as a proxy for life years lost among infants living with HIV in the absence of ART. 518 
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Table 3 The potential costs, effectiveness and cost-effectiveness of implementing a quality 519 
assurance system (QAS) in five African countries, compared to varying rates of misdiagnosis 520 





with QAS  












Kenya      
Cost of QAS ($) US$208,532     
Cost of treating false positive infants ($) $20,206 $336,765 $673,531 $1,616,117 $308,702 
DALYs lost by missing HIV positive infants 1,141 19,016 38,031 61,811 22,582 
Incremental cost S ($)  $-108,028 $-444,793 $-1,387,379 $-79,964 
Incremental DALYs averted   
17,875 36,890 60,670 21,441 
ICER ($/DALY averted)  Cost saving Cost saving Cost saving Cost saving 
South Africa      
Cost of QAS ($) US$69,359     
Cost of treating false positive infants ($) $29,885 $383,136 $766,272 $1,532,544 $351,208 
DALYs lost by missing HIV positive infants 369 4,728 9,455 18,910 5,553 
Incremental cost S ($)  
$-283,893 $-667,029 $-1,433,301 $-251,965 
Incremental DALYs averted   4,359 9,086 18,542 5,184 
ICER ($/DALY averted)  Cost saving Cost saving Cost saving Cost saving 
Senegal      
Cost of QAS ($) US$102,853     
Cost of treating false positive infants ($) $1,859 $5,808 $11,616 $23,232 $5,324 
DALYs lost by missing HIV positive infants 436 1,362 2,723 5,446 1,636 
Incremental cost S ($)  
$98,904 $93,096 $81,480 $99,388 
Incremental DALYs averted   
926 2,287 5,011 1,200 
ICER ($/DALY averted)  
$107 $41 $16 $83 
Uganda      
Cost of QAS ($) US$203,330     
Cost of treating false positive infants ($) $739,030 $739,030 $739,030 $739,030 $677,444 
DALYs lost by missing HIV positive infants 764 19,701 30,553 61,107 23,890 
Incremental cost S ($)  $-498,748 $-1,237,778 $-2,715,837 $-437,162 
Incremental DALYs averted   18,937 29,790 60,343 23,126 
ICER ($/DALY averted)  Cost saving Cost saving Cost saving Cost saving 
Zimbabwe      
Cost of QAS ($) US$334,342     
Cost of treating false positive infants ($) $44,014 $700,859 $1,401,719 $2,803,437 $642,454 
DALYs lost by missing HIV positive infants 445 7,092 14,185 28,370 8,558 
Incremental cost S ($)  
$-322,503 $-1,023,363 $-2,425,082 $-264,099 
Incremental DALYs averted   
6,647 13,739 27,924 8,113  




Table 4 Univariate sensitivity analyses of incremental cost-effectiveness ratio ($ per disability life years averted) using base case (i.e. 5% 523 





Green box = cost-saving (CS), Orange box = ICER within 1 times GDP, * Base case: 3% discount rate, 2 years of treatment averted, 0 months of testing interruption, 529 
infant access to treatment variable depending on the country – see Table 1, no loss to follow up on ART.  530 
  Kenya  South Africa Senegal Uganda Zimbabwe 
Base case*  CS CS $107 CS CS 
Discount rate 1% CS CS $56 CS CS 
5% CS CS $184 CS CS 
Number of years of 
treatment averted 
5 year CS CS $102 CS CS 
10 years CS CS $94 CS CS 
20 years CS CS $80 CS CS 
Testing interruption 
duration per year 
1 month CS CS $83 CS CS 
6 months CS CS $40 CS CS 
Infant access to 
treatment 
50% $3 CS $109 CS $1 
75% CS CS $108 CS CS 
Loss to follow up in 
ART  





Figure 1.1 Numbers of false negative EID results in a year in five African nations by HIV prevalence and the size of the gap in testing coverage.  533 
Senegal has a very low HIV prevalence, but very large gap in screening for EID, while South Africa has a high HIV prevalence and small 534 
number of infants born to HIV infected mothers who do not get tested.  The size of outer grey circles represent the number of HIV + infants that 535 
would not be identified in the absence of a quality assurance system, and the small inner black circles represent what may be achievable by 536 




Figure 1.2 Comparison of the numbers of false positive results in a year in five African nations with a quality assurance system (QAS) (black 539 
circles) compared with no QAS (grey circle)  540 
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Supplement 1 – Further details of the model. 541 
 We assumed that even in the best-case scenario at clinic level with quality assurance system 542 
in place, some misdiagnosis would persist, due to the innate sensitivity and specificity of the 543 
test. This was estimated using a sensitivity of 98.5% and specificity of 99.9%,(1) assumed to 544 
be the best realistic estimate. Misdiagnosis rates are assumed, with worst case scenario set to 545 
be the minimum level of misdiagnosis that could be identified by a five-member panel as 546 
commonly used for proficiency testing among providers. Identifying one incorrect result, 547 
implies a 20% (1/5) misdiagnosis and would be the minimum level that would trigger 548 
corrective action. A field-evaluation of POC for EID in South Africa found an error rate of 549 
9%,(34) thus we explore a 10% misdiagnosis. A 5% misdiagnosis was also explored, roughly 550 
corresponding to the 95% confidence interval of clinic POC for EID as presented by Jani, et 551 
al. and is used as the central estimate.(1) False positive and negative rates were calculated using 552 
Bayes’ Rule to solve conditional probabilities (Supplement  1).(35)  553 
 554 
To calculate the costs of a false positive result, we estimated the cost of providing ART for an 555 
infant who is not HIV-infected in each respective country and multiplied this by the national 556 
rate of access to paediatric ART, ranging from 26% in Senegal to 49% in South Africa. To 557 
calculate the health impact of a false negative result in terms of DALYs lost, we separated 558 
those with and without access to treatment. For infants with access to treatment we assume 559 
normal life expectancy.(36) For untreated infants, we estimated that 50% of infants would die 560 
by age two, and 100% would die by age 21, and used the WHO country life tables to estimate 561 
the potential years of life left at the time of death.(11, 32, 37) We applied disability weights 562 




The model was designed to undertake threshold analyses in two dimensions: 1) Above which 565 
misdiagnosis rate will each quality assurance system be cost-saving i.e. where the averted 566 
treatment costs are greater than the quality assurance system costs, and so any DALYs averted 567 
occur at no additional cost; and 2) How cheap must the quality assurance system be to be cost- 568 
saving? It is important to note that at higher quality assurance system costs or lower rates of 569 
misdiagnosis, the quality assurance system can still be cost-effective to introduce and needs to 570 
be compared against the cost-effectiveness of competing programmes or country-specific cost-571 
effectiveness thresholds. We use one-times the gross domestic product (GDP) per capita,(32) 572 
albeit under increasing criticism for being too high.(39)  Treatment costs averted can be chosen 573 
as 2, 5, 10 and 20, with 2 being the used as the default.  574 
 575 
The participating countries represent very different epidemic settings with annual pregnancies 576 
in HIV infected women ranging from 2,000 in Senegal to 220,000 in South Africa. All 577 
countries have high rates of antenatal care coverage (93-96%) but vary widely in their coverage 578 
of infant testing (12%-87%). Our model evaluates the incremental cost-effectiveness within 579 
the context of scaling up POCT EID to address this ‘testing gap’.580 
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Supplement 2:  Sensitivity analysis*: cost effectiveness planes. 
Kenya Senegal South Africa 
   
Uganda Zimbabwe  
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